Curocell
Financials
Valuation Metrics
Curocell's Market Cap is ₩3540B. At end of 2025 it was ₩6845B. Ranked #558 of 2,405 in KR market (top 23%), #223 of 1,627 on KOSDAQ (top 14%), #58 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 25%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 354.03B KRW | KR#558/2,405 Sec#58/231 |
| Revenue | 0 KRW | KR#2,381/2,405 Sec#227/231 |
| Net Income | -54.08B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 164.61B KRW | KR#1,438/2,405 Sec#110/231 |
| Net Assets | 72.52B KRW | KR#1,651/2,405 Sec#137/231 |
| Employees | 126 | KR#1,458/2,405 Sec#116/231 |
| Value | ||
| P/B | 4.88x | KR#2,254/2,405 Sec#194/231 |
| FCF Yield | -8.56% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -74.57% | KR#2,312/2,405 Sec#212/231 |
| ROA | -32.85% | KR#2,314/2,405 Sec#204/231 |
| Financial Health | ||
| Debt Ratio | 126.98% | KR#1,756/2,405 Sec#196/231 |
| Total Debt | 58.67B KRW | KR#939/2,405 Sec#62/231 |
| FCF | -30.31B KRW | KR#1,981/2,405 Sec#192/231 |
| Cash | 17.15B KRW | KR#1,339/2,405 Sec#104/231 |
| Current Ratio | 1.82x | KR#961/2,405 Sec#107/231 |
| Performance | ||
| 1Y Return | -38.08% | KR#1,694/2,405 Sec#138/231 |
| 1M Return | 1.09% | KR#280/2,405 Sec#30/231 |
| From 52W High | -64.77% | KR#1,877/2,405 Sec#158/231 |
| 1Y MDD | -67.92% | KR#1,859/2,405 Sec#157/231 |
| Trading | ||
| Volume | 21,102 shares | KR#1,452/2,405 Sec#143/231 |
| Trading Value | 489.1M KRW | KR#808/2,405 Sec#86/231 |
| Foreign Own. | 1.63% | KR#1,771/2,405 Sec#173/231 |
| Per Share | ||
| EPS | -3,552 KRW | KR—/2,405 Sec—/231 |
| BPS | 4,763 KRW | KR#1,547/2,405 Sec#112/231 |
Company Info
Qurocell was established in 2016 as a specialized enterprise for CAR-T therapeutic agent development and listed on the KOSDAQ market in 2023. The company holds several new drug pipelines, including CD19 CAR-T therapeutic agents, and completed clinical trials for Limcato, which applies OVIS™ CAR-T technology. Aiming for a 2025 product launch, it completed a manufacturing facility and applied for product approval in 2024, while also exploring expanded development for various cancer types and overseas market entry. Qurocell is headquartered in Yuseong-gu, Daejeon Metropolitan City.